Method to induce neovascular formation and tissue regeneration
Abstract
The present invention relates, e.g., to a method for inducing arteriogenesis, lymphangiogenesis, vasculogenesis, or cardiomyogenesis, and/or for inducing mitosis or proliferation of a smooth muscle cell, a skeletal muscle cell, or a cardiomyocyte, comprising administering to a cell or tissue in need thereof a dose of a polynucleotide that encodes a vascular endothelial growth factor (VEGF), or that encodes a polypeptide comprising an active site of the VEGF. The coding sequence is operably linked to an expression control sequence; and the dose is sufficient to induce arteriogenesis, lymphangiogenesis, vasculogenesis, or cardiomyogenesis, and/or to induce mitosis or proliferation of a smooth muscle cell, a skeletal muscle cell, or a cardiomyocyte. In preferred embodiments of the invention, the method is a method of tissue regeneration, particularly of cardiomyogenesis; and the polynucleotide (or a polypeptide encoded by such a polynucleotide) is administered into the myocardium.
Claims
exact text as granted — not AI-modified1 . A method for inducing arteriogenesis, lymphangiogenesis, vasculogenesis, or cardiomyogenesis in a cell or tissue in need thereof, comprising administering directly to the cell or tissue a dose of a polynucleotide that encodes the vascular endothelial growth factor, VEGF 1-165, or that encodes a polypeptide comprising an active variant of the VEGF 1-165, wherein the coding sequence is operably linked to a CMV promoter and is in a plasmid vector, the dose being in a sufficient amount to induce arteriogenesis, lymphangiogenesis, vasculogenesis, or cardiomyogenesis.
2 . The method of claim 1 , wherein the VEGF 1-165 has the amino acid sequence:
(SEQ ID NO: 1)
Ala Pro Met Ala Glu Gly Gly Gly Gln Asn
His His Glu Val Val Lys Phe Met Asp Val
Tyr Gln Arg Ser Tyr Cys His Pro Ile Glu
Thr Leu Val Asp Ile Phe Gln Glu Tyr Pro
Asp Glu Ile Glu Tyr Ile Phe Lys Pro Ser
Cys Val Pro Leu Met Arg Cys Gly Gly Cys
Cys Asn Asp Glu Gly Leu Glu Cys Val Pro
Thr Glu Glu Ser Asn Ile Thr Met Gln Ile
Met Arg Ile Lys Pro His Gln Gly Gln His
Ile Gly Glu Met Ser Phe Leu Gln His Asn
Lys Cys Glu Cys Arg Pro Lys Lys Asp Arg
Ala Arg Gln Glu Asn Pro Cys Gly Pro Cys
Ser Glu Arg Arg Lys His Leu Phe Val Gln
Asp Pro Gln Thr Cys Lys Cys Ser Cys Lys
Asn Thr Asp Ser Arg Cys Lys Ala Arg Gln
Leu Glu Leu Asn Glu Arg Thr Cys Arg Cys
Asp Lys Pro Arg Arg.
3 . The method of claim 1 , wherein the arteriogenesis, lymphangiogenesis, vasculogenesis, or cardiomyogenesis is induced in vitro or ex vivo.
4 . The method of claim 1 , wherein the arteriogenesis, lymphangiogenesis, vasculogenesis, or cardiomyogenesis is induced in ischemic tissue, in vitro or ex vivo.
5 . A method for inducing arteriogenesis, lymphangiogenesis, vasculogenesis, or cardiomyogenesis in a subject in need of such treatment, comprising administering to the subject a dose of a VEGF 1-165 polypeptide, or of an active variant thereof, which is sufficient to induce arteriogenesis, lymphangiogenesis, vasculogenesis, or cardiomyogenesis.Join the waitlist — get patent alerts
Track US2009275645A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.